LifeStyle

• 
  Celltrion's antibody COVID-19 treatment wins approval from S. Korean state watchdog SEOUL -- South Korea's drug safety watchdog approved Celltrion's antibody treatment code-named CT-P59, which has been developed as an intravenous injection for patients. It became South Korea's first treatment for COVID-19. As CT-P59 has the advantage of forming antibodies immediately after administration, medical personnel and other vulnerable people will be able to prevent infections. The Ministry of Food and Drug Safety decided to grant permission on the condition tha 2021-02-05
• 
  Experts give conditional consent to AstraZeneca's vaccine for people over 65 SEOUL -- South Korean experts gave conditional consent to the use of British-Swedish drugmaker AstraZeneca's COVID-19 vaccine for old people over the age of 65, saying that preventive effects have been confirmed in all age groups, along with a good safety profile. The Ministry of Food and Drug Safety has consulted an advisory group of eight experts to address concerns that the AstraZeneca vaccine, created in conjunction with the University of Oxford, could be less effective in p 2021-02-01
• 
  Canada approves Celltrion's subcutaneous injection for rheumatoid arthritis indication SEOUL -- Celltrion's Remsima SC, the subcutaneous injection of Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease, has secured approval from Canada's state health watchdog. Celltrion saw the green light as a bridgehead for its entry into the United States. Remsima SC can be injected into the fat layer beneath the skin at home. Celltrion, a leading biosimilar manufacturer in South Korea, said on February 1 that Health Can 2021-02-01
• 
  GC Labcell exports original technology for U.S. deal to develop cell therapies SEOUL -- GC Labcell, a manufacturer of cell therapy products in South Korea, will export its original platform technology and participates in joint research with its U.S. partner under a deal with Merck, an American pharmaceutical company, to develop novel chimeric antigen receptor-natural killer cell therapies targeting solid tumor-associated antigens. GC Labcell said in a regulatory filing on January 29 that Artiva Biotherapeutics, a San Diego-based oncology company founded by S 2021-01-29